Supportive Care | Specialty

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

Supporting Adolescents and Young Adults With Cancer From Diagnosis Through Survivorship

September 14th 2015

Due to the unique characteristics of adolescents and young adults, there is a growing effort to address their oncology needs.

Three Priority Review Designations, Zarxio Now Available, Rolapitant Approved, and More

September 11th 2015

FDA-Approved Rolapitant Offers New Option for CINV

September 10th 2015

Marleen Meyers, MD, discusses rolapitant (Varubi), which the FDA recently approved to prevent delayed CINV.

First US Biosimilar Finally Reaches Market

September 3rd 2015

The first FDA-approved biosimilar, Zarxio, is now available for patients in the United States, following a series of lawsuits and court decisions.

Dr. Alberto Montero on Reducing Readmission Rates for Oncology Patients

September 2nd 2015

Alberto Montero, MD Staff Physician in the Department of Solid Tumor Oncology, Cleveland Clinic, discusses reducing readmission rates for oncology patients.

FDA Expands Aprepitant's CINV Indication

September 2nd 2015

The FDA has approved aprepitant capsules in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting in patients aged 12 to 17 and for those under the age of 12 who weigh at least 30 kg who are receiving chemotherapy.

FDA Approves Rolapitant for CINV

September 2nd 2015

The FDA has approved rolapitant (Varubi) for use in combination with other antiemetic agents to prevent delayed CINV.

Eltrombopag Approval, Cabozantinib Breakthrough Designation, Pembrolizumab Priority Review, and More

August 28th 2015

Rapidly Evolving Lung Cancer Treatment Landscape

August 27th 2015

Checkpoint Inhibitors for Malignant Pleural Mesothelioma

August 27th 2015

Immunotherapy AEs and Treatment Duration in NSCLC

August 27th 2015

Checkpoint Inhibitors in Small-Cell Lung Cancer

August 27th 2015

Frontline Immunotherapy Combinations for NSCLC

August 27th 2015

Checkpoint Inhibitor Biomarkers for Lung Cancer

August 27th 2015

Emerging Landscape of Immunotherapy in NSCLC

August 27th 2015

Bevacizumab in EGFR-Mutant NSCLC

August 27th 2015

Bevacizumab in Nonsquamous NSCLC

August 27th 2015

Bevacizumab in Malignant Pleural Mesothelioma

August 27th 2015

New Therapies for Squamous NSCLC

August 27th 2015

Cabozantinib in RET-Rearranged NSCLC

August 27th 2015